REG - hVIVO PLC - Long Term Incentive Plan / PDMR Notification

hVIVOAnnouncement

15/02/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240215:nRSO1878Da&default-theme=true

RNS Number : 1878D  hVIVO PLC  15 February 2024

hVIVO plc

("hVIVO" or the "Company")

 

Long Term Incentive Plan / PDMR Notification

 

hVIVO plc (AIM & Euronext: HVO), a rapidly growing specialist contract
research organisation (CRO) and world leader in testing infectious and
respiratory disease products using human challenge clinical trials, announces
that the Company has granted options to Stephen Pinkerton, Chief Financial
Officer, under its Long Term Incentive Plan ("LTIP").

 

The LTIP has been designed to reward, incentivise and retain Mr Pinkerton to
deliver sustainable growth for shareholders. Under the rules of the LTIP, the
deemed date of award is 1 February 2023 following his appointment to the role
in October 2022. Under the LTIP, Mr Pinkerton has been awarded 2,433,824
nominal cost long term incentive options ("LTIP Options") over ordinary shares
of £0.001 each in the Company.

 

Vesting of the LTIP Options is conditional upon a three-year total shareholder
return ("TSR") performance against an initial 17p reference price. The LTIP
Options will vest on the third anniversary of the date of award subject to the
achievement of a minimum 10% CAGR TSR performance increasing on a
straight-line basis to vesting in full subject to the achievement of a 22.5%
CAGR TSR performance.

 

For further information please contact:

 

 hVIVO plc                                           +44 (0) 20 7756 1300
 Yamin 'Mo' Khan, Chief Executive Officer

 Stephen Pinkerton, Chief Financial Officer

 Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker)        +44 (0) 20 7220 0500
 Geoff Nash, Charlie Beeson, Nigel Birks, Harriet Ward

 Peel Hunt LLP (Joint Broker)                                                  +44 (0)20 7418 8900
 James Steel, Dr Christopher Golden

 Davy (Euronext Growth Adviser and Joint Broker)                               +353 (0) 1 679 6363
 Anthony Farrell, Niall Gilchrist

 Walbrook PR (Financial PR & IR)                     +44 (0) 20 7933 8780 or hvivo@walbrookpr.com

 Stephanie Cuthbert / Phillip Marriage /             +44 (0) 7796 794 663 / +44 (0) 7867 984 082 /

Louis Ashe-Jepson
+44 (0) 7747 515 393

 

Notes to Editors

 

About hVIVO

 

hVIVO plc (http://www.hvivo.com) (ticker: HVO) (formerly Open Orphan plc) is
a rapidly growing specialist contract research organisation (CRO) and the
world leader in testing infectious and respiratory disease vaccines and
therapeutics using human challenge clinical trials. The Group provides
end-to-end early clinical development services to its large, established and
growing repeat client base, which includes four of the top 10 largest global
biopharma companies.

 

The Group's fast-growing services business includes a unique portfolio of 11
human challenge models, with a number of new models under development, to test
a broad range of infectious and respiratory disease products. The Group has
world class challenge agent manufacturing capabilities, specialist drug
development and clinical consultancy services via its Venn Life Sciences
brand, and a lab offering via its hLAB brand, which includes virology,
immunology biomarker and molecular testing. The Group offers additional
clinical field trial services such as patient recruitment and clinical trial
site services.

 

hVIVO runs challenge studies in London from its Whitechapel quarantine
clinic, its state-of-the-art QMB clinic with its highly specialised on-site
virology and immunology laboratory, and its clinic in Plumbers Row. To
recruit volunteers / patients for its studies, the Group leverages its unique
clinical trial recruitment capability via its FluCamp
(http://www.flucamp.com/) volunteer screening facilities in London and
Manchester.

 

Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them:

 

 1   Details of the person discharging managerial responsibilities/person closely
     associated
 a.  Name of PDMR                                                 Stephen Pinkerton
 2   Reason for notification

 a.  Position/Status                                              CFO
 b.  Initial notification/                                        Initial

     Amendment
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a.  Name                                                         hVIVO plc
 b.  LEI                                                          213800VT5KBM7JLIV118
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a.  Description of the financial instrument, type of instrument  Ordinary shares of £0.001 each

     Identification Code

                                                                  ESVUFR

                                                                  ISIN  GB00B9275X97
 b.  Nature of the transaction                                    Grant of options under LTIP
 c.  Price(s) and volume(s)                                       Price(s)                    Volume(s)
     0.001                                                                                    2,433,824
 d.  Aggregated information

                                                                  2,433,824

     - Aggregated Volume                                          0.001

     - Price
 e.  Date of the transaction                                      14 February 2024
 f.  Place of the transaction                                     Outside a trading venue

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHFLFEDFRISLIS